Erschienen in:
01.06.2014 | Childhood and Adolescent Headache (S Evers, Section Editor)
Preventive Drugs in Childhood and Adolescent Migraine
verfasst von:
Joanne Kacperski, Andrew D. Hershey
Erschienen in:
Current Pain and Headache Reports
|
Ausgabe 6/2014
Einloggen, um Zugang zu erhalten
Abstract
While headaches in children are quite common, the study and characterization of headache disorders in the pediatric age group has historically been limited. In the absence of controlled studies on prophylactic treatment of the primary headache disorders in this age group, the diagnosis of childhood migraine rests on criteria similar to those in adults. Data from adult studies are often extrapolated and applied to children as well. Although it appears that many preventive agents are safe in children, none are currently FDA-approved for this age group. As a result, despite experiencing significant disability, the vast majority of children who present to their physician with migraine headache do not receive prophylactic therapy. Furthermore, controlled clinical trials investigating the use of both abortive and preventive medications in children have suffered from high placebo response rates. The shorter duration of headaches and other characteristic features seen in children are such that designing randomized controlled trials in this age group is more problematic and limiting. As such, treatment practices vary widely, even among specialists, due to the absence of evidence-based guidelines from clinical trials.